<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639625</url>
  </required_header>
  <id_info>
    <org_study_id>300CX02AR01</org_study_id>
    <nct_id>NCT01639625</nct_id>
  </id_info>
  <brief_title>Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application</brief_title>
  <official_title>Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorio Elea Phoenix S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorio Elea Phoenix S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      They include patients who are candidates to complete concurrent treatment with endocavitary&#xD;
      brachytherapy External radiation therapy + more QT based weekly cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with presence or absence of grade 3 or 4 adverse events related to the study drug, in each dose level</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with local relapses</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with distant relapses</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Squamous Cell Carcinoma of the Cervix</condition>
  <condition>Adenocarcinoma of the Cervix</condition>
  <arm_group>
    <arm_group_label>CIGB300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIGB300</intervention_name>
    <description>CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.</description>
    <arm_group_label>CIGB300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stages IIA and IIB FIGO classification.&#xD;
&#xD;
          -  Age between 21 to 70 years.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  No history of another neoplastic disease.&#xD;
&#xD;
          -  Value of Hemoglobin ≥ 9 g / l.&#xD;
&#xD;
          -  Total leukocyte count ≥ 3.0 x 109 / L.&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 109 / L.&#xD;
&#xD;
          -  Platelets ≥ 100,000 x mm3.&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN, SGOT and SGPT ≤ 2.5 times upper limit of normal.&#xD;
&#xD;
          -  Creatinine ≤ 2 mg / dL and creatinine clearance calculated ≥ 60 ml / min(according to&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          -  Patients of childbearing age who are using an adequate contraception method during&#xD;
             treatment to prevent pregnancy.&#xD;
&#xD;
          -  Life expectancy ≥ 12 months&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and lactation period.&#xD;
&#xD;
          -  Presence of lymph node metastases or hematogenous extrapelvic known.&#xD;
&#xD;
          -  Uncontrolled intercurrent diseases, including active infection, symptomatic congestive&#xD;
             heart failure, unstable angina or cardiac arrhythmia and psychiatric illness involving&#xD;
             incompetence of the patient.&#xD;
&#xD;
          -  Other malignancies, with the exception of basal cell carcinoma or other tumor that&#xD;
             appropriate treatment is received showing a disease-free period ≥ 5 years.&#xD;
&#xD;
          -  Hepatitis B or C active, positive serology for HIV.&#xD;
&#xD;
          -  Atopy history of severe / severe asthma.&#xD;
&#xD;
          -  A history of autoimmune disease.&#xD;
&#xD;
          -  Presence of significant abnormalities in ECG performed within 14 days prior to&#xD;
             admission.&#xD;
&#xD;
          -  Diseases that prevent the patient give informed consent or their ability to&#xD;
             collaborate in the trial.&#xD;
&#xD;
          -  Participating in another clinical trial &quot;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Oncologia Angel H. Roffo</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1417DTB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

